WIRTH PETER - 05 Jun 2024 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Reporting relationship: Director
Issuer ticker: SYRS
Reported as of: 05 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Jun 2024, 16:30:05 UTC
Prior SEC filing: 30 Jun 2023
Next SEC filing: 20 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Todd Rosenthal, as attorney-in-fact

Key filing fact

WIRTH PETER filed Form 4 for Syros Pharmaceuticals, Inc. (SYRS) on 07 Jun 2024.

Key facts

This page summarizes WIRTH PETER's Form 4 filing for Syros Pharmaceuticals, Inc. (SYRS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 Jun 2024, 16:30.

Change

Previous filing in this sequence was filed on 30 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SYRS transaction

Common Stock

Award

Transaction value: $0
Shares: +4,000
Change %: +33%
Price: $0.000000
Shares after: 16,000
Date: 05 Jun 2024
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SYRS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +6,000
Change %
Price: $0.000000
Shares after: 6,000
Date: 05 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,000
Exercise price: $5.30
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.